Literature DB >> 19360410

DNase1 exon2 analysis in Tunisian patients with rheumatoid arthritis, systemic lupus erythematosus and Sjögren syndrome and healthy subjects.

Salima Belguith-Maalej1, Hassen Hadj-Kacem, Neila Kaddour, Zouhir Bahloul, Hammadi Ayadi.   

Abstract

Autoimmune diseases (AID) are caused by the loss of immunological tolerance against self-antigens. The deoxyribonuclease I (DNASE1) gene seems to participate in the genetic susceptibility of some AID. In fact, two mutations were reported among systemic lupus erythematosus (SLE) patients from Japan and Spain (the 172 A → T mutation (K5X) and the 46_72 deletion, respectively). The aim of our work was to evaluate the DNASE1 contribution in the genetic susceptibility of rheumatoid arthritis (RA, n = 151), Sjögren syndrome (SS, n = 55) and SLE (n = 34) in Tunisia. DNA from patients and healthy subjects (n = 232) were explored. Both reported mutations were absent among patient and control subjects. The DNASE1 exon2 sequence was analysed among 26 control subjects to identify new polymorphic variations that are possible. Five known SNPs were explored. The G/T transversion (rs8176927: R2S) was the most polymorphic functional nonsynonymous SNP. Using PCR-RFLP method, all DNAs were genotyped for rs8176927 for a case-control design. The statistical analysis showed no significant differences between patients and controls genotype data. In conclusion, our study showed, on the one hand, the absence of the K5X mutation and the 46_72 deletion in Tunisian patients affected with RA, SS and SLE and healthy subjects, and, on the other hand, the absence of association between the R2S polymorphism and the genetic susceptibility of RA, SS and SLE.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19360410     DOI: 10.1007/s00296-009-0917-4

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  32 in total

1.  Features of systemic lupus erythematosus in Dnase1-deficient mice.

Authors:  M Napirei; H Karsunky; B Zevnik; H Stephan; H G Mannherz; T Möröy
Journal:  Nat Genet       Date:  2000-06       Impact factor: 38.330

2.  DNASE I mutation and systemic lupus erythematosus in a Spanish population: comment on the article by Tew et al.

Authors:  Eva Balada; Josep Ordi-Ros; Susana Hernanz; Julieta Villarreal; Fina Cortés; Miquel Vilardell-Tarrés; Moisés Labrador
Journal:  Arthritis Rheum       Date:  2002-07

3.  The A/T mutation in exon 2 of the DNASE1 gene is not present in Tunisian patients with systemic lupus erythematosus or in healthy subjects.

Authors:  Pampa Chakraborty; Hassen Hadj Kacem; Kauothar Makni-Karray; Faiçal Jarraya; Jamil Hachicha; Hammadi Ayadi
Journal:  Arthritis Rheum       Date:  2003-11

4.  Scleroderma overlap syndromes.

Authors:  S Jablonska; M Blaszczyk
Journal:  Adv Exp Med Biol       Date:  1999       Impact factor: 2.622

5.  Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus.

Authors:  M C Hochberg
Journal:  Arthritis Rheum       Date:  1997-09

Review 6.  A new function for an old enzyme: the role of DNase I in apoptosis.

Authors:  H G Mannherz; M C Peitsch; S Zanotti; R Paddenberg; B Polzar
Journal:  Curr Top Microbiol Immunol       Date:  1995       Impact factor: 4.291

7.  Measurement of deoxyribonuclease I (DNase) in the serum and urine of systemic lupus erythematosus (SLE)-prone NZB/NZW mice by a new radial enzyme diffusion assay.

Authors:  M Macanovic; P J Lachmann
Journal:  Clin Exp Immunol       Date:  1997-05       Impact factor: 4.330

8.  The treatment of systemic lupus erythematosus (SLE) in NZB/W F1 hybrid mice; studies with recombinant murine DNase and with dexamethasone.

Authors:  M Macanovic; D Sinicropi; S Shak; S Baughman; S Thiru; P J Lachmann
Journal:  Clin Exp Immunol       Date:  1996-11       Impact factor: 4.330

Review 9.  DNaseI in pathogenesis of systemic lupus erythematosus.

Authors:  Shin-Ichi Tsukumo; Koji Yasutomo
Journal:  Clin Immunol       Date:  2004-10       Impact factor: 3.969

10.  Actin is the naturally occurring inhibitor of deoxyribonuclease I.

Authors:  E Lazarides; U Lindberg
Journal:  Proc Natl Acad Sci U S A       Date:  1974-12       Impact factor: 11.205

View more
  7 in total

1.  Anti-DNase I antibodies in systemic lupus erythematosus: diagnostic value and share in the enzyme inhibition.

Authors:  A S Trofimenko; I P Gontar; A B Zborovsky; O V Paramonova
Journal:  Rheumatol Int       Date:  2016-02-15       Impact factor: 2.631

Review 2.  Pathophysiology and Genetics of Bronchiectasis Unrelated to Cystic Fibrosis.

Authors:  Aleksandra Nikolic
Journal:  Lung       Date:  2018-05-12       Impact factor: 2.584

Review 3.  Clinical perspectives on lupus genetics: advances and opportunities.

Authors:  Judith A James
Journal:  Rheum Dis Clin North Am       Date:  2014-06-10       Impact factor: 2.670

4.  Impaired deoxyribonuclease I activity in patients with inflammatory bowel diseases.

Authors:  Karin Malíčková; Dana Duricová; Martin Bortlík; Zdenka Hrušková; Barbora Svobodová; Naděžda Machková; Viktor Komárek; Terezie Fučíková; Ivana Janatková; Tomáš Zima; Milan Lukáš
Journal:  Autoimmune Dis       Date:  2011-05-29

5.  DNase1: No Association with Crohn's Disease in a New Zealand Population.

Authors:  Angharad R Morgan; Wen-Jiun Lam; Dug-Yeo Han; Alan G Fraser; Lynnette R Ferguson
Journal:  ISRN Gastroenterol       Date:  2012-06-04

6.  Investigation of Caucasian rheumatoid arthritis susceptibility loci in African patients with the same disease.

Authors:  Sebastien Viatte; Edward Flynn; Mark Lunt; Joanne Barnes; Madeleine Singwe-Ngandeu; Sylvette Bas; Anne Barton; Cem Gabay
Journal:  Arthritis Res Ther       Date:  2012-11-03       Impact factor: 5.156

7.  Evaluation of the functional effects of genetic variants‒missense and nonsense SNPs, indels and copy number variations‒in the gene encoding human deoxyribonuclease I potentially implicated in autoimmunity.

Authors:  Misuzu Ueki; Kaori Kimura-Kataoka; Junko Fujihara; Reiko Iida; Yasuyuki Kawai; Akari Kusaka; Takamitsu Sasaki; Haruo Takeshita; Toshihiro Yasuda
Journal:  Sci Rep       Date:  2019-09-20       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.